A Martinez-Marti
Overview
Explore the profile of A Martinez-Marti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
811
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A, et al.
Ann Oncol
. 2023 Jul;
34(10):907-919.
PMID: 37467930
Background: IMpower010 (NCT02486718) demonstrated significantly improved disease-free survival (DFS) with adjuvant atezolizumab versus best supportive care (BSC) following platinum-based chemotherapy in the programmed death-ligand 1 (PD-L1)-positive and all stage II-IIIA...
2.
Cedres S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, et al.
Clin Transl Oncol
. 2020 Jan;
22(8):1390-1398.
PMID: 31916017
Background: Promising results have been reported with immune checkpoint inhibitors (ICI) in a small proportion of MPM patients. MMR deficiency (dMMR) has been well described in several malignancies and was...
3.
Domingues I, Cedres S, Callejo A, Vivancos A, Martinez-Marti A, Felip E
Pulmonology
. 2019 Aug;
26(1):49-50.
PMID: 31401029
No abstract available.
4.
Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, et al.
Lung Cancer
. 2019 Jun;
133:83-87.
PMID: 31200833
Objectives: Chemo-radiotherapy (CRT) and concurrent PD-1 inhibition has shown promising results in pre-clinical models. So far, the feasibility of delivering concurrent CRT and PD-1/PD-L1 inhibition has never been assessed in...
5.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, et al.
Ann Oncol
. 2019 May;
30(8):1321-1328.
PMID: 31125062
Background: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly...
6.
Remon J, Pardo N, Martinez-Marti A, Cedres S, Navarro A, Martinez de Castro A, et al.
Lung Cancer
. 2018 Feb;
117:80.
PMID: 29398170
No abstract available.
7.
Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedres S, et al.
Ann Oncol
. 2017 Sep;
28(10):2451-2457.
PMID: 28961841
Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. Different...
8.
Remon J, Pardo N, Martinez-Marti A, Cedres S, Navarro A, Martinez de Castro A, et al.
Lung Cancer
. 2017 Mar;
106:70-75.
PMID: 28285697
Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with...
9.
Cedres S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, et al.
Lung Cancer
. 2016 May;
96:1-6.
PMID: 27133741
Background: Malignant pleural mesothelioma (MPM) frequently express elevated AKT/mTOR activity. Previous reports in gliomas, colon, breast and prostate cancer suggest that PTEN/PI3K pathway may be important for the induction of...
10.
Felip E, Martinez-Marti A
Ann Oncol
. 2012 Jun;
23(9):2211-2214.
PMID: 22684743
No abstract available.